# Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer

> **NCT00362882** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 81 (actual)

## Conditions studied

- Non-small Cell Lung Cancer
- Recurrent Non-small Cell Lung Cancer
- Stage IV Non-small Cell Lung Cancer

## Interventions

- **DRUG:** docetaxel
- **DRUG:** bortezomib
- **OTHER:** laboratory biomarker analysis
- **OTHER:** immunoenzyme technique
- **OTHER:** immunohistochemistry staining method
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00362882
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2017-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00362882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00362882, "Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00362882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*